Buy Rating for Nuvectis Pharma’s NXP900 Driven by Promising Efficacy and Development Progress
I'm PortAI, I can summarize articles.
Naz Rahman from Maxim Group maintains a Buy rating on Nuvectis Pharma with a $17.00 price target, driven by the promising efficacy of NXP900, a Src family kinase inhibitor. The drug is in Phase 1b trials for cancer patients resistant to EGFR and ALK inhibitors. Positive data from a similar drug supports its potential. H.C. Wainwright also reiterated a Buy rating with a $10.00 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments